Nurix Therapeutics Inc at the ASH Annual Meeting Transcript
Okay, great. Let's get started. My name is Jason Kantor. I'm Chief Business Officer here at nerd therapeutics. I'd like to welcome everyone here who's in the room in San Diego and to all the folks on the webcast. Welcome to nourish therapeutics, ASH 2023 analyst event. We've got a lot of data to share with you tonight. It was a good day here at ASH with the posters for 2.275948, and I'd like to welcome up to the podium. Neurodex is President and CEO. Dr. Arthur Sands. Arthur.
Thanks, Jason. And I'd also like to add my words of welcome to everyone and been a very exciting ASH 2023 for generics. We had a couple of major presentations at this conference, and we'll be talking about those tonight.
Before I get started, I'd like to just remind everyone we will be making certain forward-looking statements, and we refer you to our filings regarding our risk factors with the SEC. So we will be talking about two molecules tonight. And Merix
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |